Clinical Trials Logo
  1. Home
  2. Choriocarcinoma
  3. NCT02396511

TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma

Choriocarcinoma Clinical Trial

Official title:
Patient Treatment Protocol of TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma

Clinical Trial Summary

The purpose of this study is to determine whether TRC105 in combination with Bevacizumab is effective in the treatment of two patients with metastatic and refractory choriocarcinoma.

Clinical Trial Description

Bevacizumab is a monoclonal antibody to vascular endothelial growth factor (VEGF) that inhibits angiogenesis and extends survival in patients with a wide variety of solid tumor types. TRC105 is a monoclonal antibody to CD105, an angiogenic target highly expressed on the tumor vessels and the tumor cells in choriocarcinoma. Together, these antibodies may be efficacious in metastatic and refractory choriocarcinoma, a tumor type that is highly vascular and expresses endoglin. The purpose of this study is to determine whether TRC105 in combination with Bevacizumab is effective in the treatment of two patients with metastatic and refractory choriocarcinoma. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02396511
Study type Interventional
Source Tracon Pharmaceuticals Inc.
Contact
Status Completed
Phase Phase 2
Start date January 2015
Completion date December 2017
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT04562558 - Biweekly Actinomycin-D Treatment or Multi-day Methotrexate Protocol in Low-risk Gestational Trophoblastic Neoplasia N/A
Terminated NCT02664961 - Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN) Phase 2
Completed NCT01535053 - Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia Phase 3
Completed NCT00190918 - A Trial for Patients With Gestational Trophoblastic Disease Phase 2
Recruiting NCT04684368 - A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT Phase 2
Recruiting NCT01267851 - Clinical Database and Biobank of Patients With Gynecologic Neoplasms
Active, not recruiting NCT02375204 - Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors Phase 3
Not yet recruiting NCT00294177 - Conformation of Beta Human Chorionic Gonadotropin During Chemotherapy for Choriocarcinoma Phase 4
Recruiting NCT05564026 - Molecular Epidemiology of Pediatric Germ Cell Tumors